精神分裂症患者的共病健康结局:系统综述与荟萃分析的伞状综述
结果显示精神分裂症与哮喘、慢性阻塞性肺疾病、肺炎、女性乳腺癌、心血管疾病、卒中、充血性心力衰竭、性功能障碍、骨折、痴呆和银屑病存在显著关联,但证据质量多为弱或无显著。
要点
- 精神分裂症与呼吸、心血管、性、神经及皮肤等多领域共病结局存在显著关联。
- 多数关联的证据质量等级为弱或无显著,仅部分结局如肺炎、痴呆等呈弱证据。
- 作者强调需采用整合治疗 approach,并需进一步研究强化证据。
核心结论
- 精神分裂症患者与多种共病健康结局存在显著关联,涉及呼吸、心血管、性、神经及皮肤等领域。
- 由于证据等级主要为无显著至弱,需进一步研究以强化理解。
研究设计与样本
- 采用AMSTAR2进行数据提取和质量评估,遵循PRISMA指南,证据可信度按质量分级,方案注册于PROSPERO(CRD42024498833)。
主要发现
- 哮喘:eRR 1.71(95% CI 1.05-2.78),证据等级=无显著。
- 慢性阻塞性肺疾病:eRR 1.73(95% CI 1.25-2.37),证据等级=弱。
- 肺炎:eRR 2.63(95% CI 1.11-6.23),证据等级=弱。
- 女性乳腺癌:eRR 1.31(95% CI 1.04-1.65),证据等级=弱。
- 心血管疾病:eRR 1.53(95% CI 1.12-2.11),证据等级=弱。
关键数值与推荐
- 卒中:eRR 1.71(95% CI 1.30-2.25),证据等级=弱。
- 充血性心力衰竭:eRR 1.81(95% CI 1.21-2.69),证据等级=弱。
- 性功能障碍:eRR 2.30(95% CI 1.75-3.04),证据等级=弱。
- 骨折:eRR 1.63(95% CI 1.10-2.40),证据等级=弱。
- 痴呆:eRR 2.29(95% CI 1.19-4.39),证据等级=弱;银屑病:eRR 1.83(95% CI 1.18-2.83),证据等级=弱。
临床怎么用
- 作者强调精神分裂症需要整合治疗 approach,因其对呼吸、心血管、性、神经和皮肤健康领域有广泛影响。
- 原文未据此给出具体临床推荐。
局限性
- 证据等级主要为无显著至弱,需进一步研究以强化理解。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
There is no comprehensive umbrella review exploring the connection between schizophrenia and various health outcomes. Therefore, we aimed to systematically review existing meta-analyses about schizophrenia-associated comorbid health outcomes and validate the evidence levels. We performed an umbrella review of meta-analyses of observational studies to explore comorbid health outcomes in individuals with schizophrenia. Searches were conducted across PubMed/MEDLINE, EMBASE, ClinicalKey, and Google Scholar up to September 5, 2023, targeting meta-analyses of observational studies related to comorbid health outcomes in individuals with schizophrenia. We applied AMSTAR2 for data extraction and quality assessment, adhering to PRISMA guidelines. Evidence credibility was evaluated and categorized by evidence quality. Our protocol was registered with PROSPERO (CRD42024498833). Risk and protective factors were analyzed and presented through equivalent odds ratios (eRR). In this umbrella review, we analyzed 9 meta-analyses, including 88 original articles, covering 21 comorbid health outcomes with over 66 million participants across 19 countries. Patients with schizophrenia showed significant associations with multiple health outcomes, including asthma (eRR, 1.71 [95% CI, 1.05-2.78], class and quality of evidence [CE] = non-significant), chronic obstructive pulmonary disease (1.73 [1.25-2.37], CE = weak), pneumonia (2.63 [1.11-6.23], CE = weak), breast cancer of female patients (1.31 [1.04-1.65], CE = weak), cardiovascular disease (1.53 [1.12-2.11], CE = weak), stroke (1.71 [1.30-2.25], CE = weak), congestive heart failure (1.81 [1.21-2.69], CE = weak), sexual dysfunction (2.30 [1.75-3.04], CE = weak), fracture (1.63 [1.10-2.40], CE = weak), dementia (2.29 [1.19-4.39], CE = weak), and psoriasis (1.83 [1.18-2.83] CE = weak). Our study underscores the imperative for an integrated treatment approach to schizophrenia, highlighting its broad impact across respiratory, cardiovascular, sexual, neurological, and dermatological health domains. Given the predominantly non-significant to weak evidence levels, further studies are needed to reinforce our understanding.
引用
- Lee H, Lee JH, Lee S, et al. Comorbid health outcomes in patients with schizophrenia: an umbrella review of systematic reviews and meta-analyses. Mol Psychiatry. 2024. PMID: 39424931. doi:10.1038/s41380-024-02792-2
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。